In Push Against Pharma Transparency Bill, Group Puts Focus On Patients Instead Of Prices
The California Life Sciences Association trade group, which says that the legislation will shift focus from research to paperwork, is launching an initiative to show the other side of skyrocketing drug prices.
San Francisco Business Times:
Price Fight For California Drug Makers As Biotech Convention Rolls In
California drug makers want to put a face other than Martin Shkreli's on the issue of drug pricing. Saying a price transparency bill in the state Legislature will shift money from research to paperwork, the California Life Sciences Association trade group is unleashing a digital campaign emphasizing patients and caregivers. The initiative is the latest in the rhetorical back-and-forth between legislators and the biopharmaceutical industry, a debate that often features Shkreli's well-documented plan as CEO of Turing Pharmaceuticals to increase the price of a generic drug treating HIV patients by 5,000 percent. (Leuty 6/6)